Plus Therapeutics, Inc. (NASDAQ:PSTV) Receives $58.00 Consensus Price Target from Analysts

Shares of Plus Therapeutics, Inc. (NASDAQ:PSTV) have received an average recommendation of “Hold” from the seven ratings firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $58.00.

A number of analysts have recently issued reports on PSTV shares. Lake Street Capital started coverage on Plus Therapeutics in a research report on Tuesday, February 3rd. They set a “buy” rating and a $50.00 price objective on the stock. HC Wainwright restated a “buy” rating and set a $25.00 price objective (down from $50.00) on shares of Plus Therapeutics in a research report on Friday, January 23rd. D. Boral Capital restated a “hold” rating on shares of Plus Therapeutics in a research report on Tuesday, March 31st. Ascendiant Capital Markets lowered their price objective on Plus Therapeutics from $475.00 to $65.00 and set a “buy” rating on the stock in a research report on Thursday, April 9th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Plus Therapeutics in a research report on Tuesday, April 21st.

Institutional Trading of Plus Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Susquehanna International Group LLP bought a new stake in shares of Plus Therapeutics during the third quarter valued at approximately $46,000. Jane Street Group LLC bought a new stake in Plus Therapeutics in the second quarter valued at $41,000. State Street Corp grew its position in Plus Therapeutics by 37.1% in the fourth quarter. State Street Corp now owns 468,893 shares of the company’s stock valued at $240,000 after acquiring an additional 127,000 shares during the period. Scientech Research LLC bought a new stake in Plus Therapeutics in the third quarter valued at $100,000. Finally, XTX Topco Ltd bought a new stake in Plus Therapeutics in the fourth quarter valued at $127,000. 3.28% of the stock is currently owned by institutional investors.

Plus Therapeutics Stock Down 9.2%

Shares of NASDAQ PSTV opened at $5.99 on Friday. The company has a market cap of $41.09 million, a P/E ratio of -0.19 and a beta of 1.03. Plus Therapeutics has a 12 month low of $2.90 and a 12 month high of $23.42. The business’s 50 day moving average is $6.18 and its two-hundred day moving average is $10.22.

Plus Therapeutics (NASDAQ:PSTV) last released its quarterly earnings data on Thursday, March 12th. The company reported $6.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $6.28. The firm had revenue of $1.37 million for the quarter, compared to the consensus estimate of $1.23 million. Sell-side analysts expect that Plus Therapeutics will post -3.66 earnings per share for the current fiscal year.

Plus Therapeutics Company Profile

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.